8-K filing — Theravance Biopharma, Inc. (TBPH)
Filed: 2026-08-25 AccNo: 0001104659-26-100860 Size: 2 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
HC Wainwright & Co. Downgrades Theravance Biopharma to Neutral, Raises Price Target to $17
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 7, 2026, 11:41 AM
- Checked
- Jul 7, 2026, 11:50 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Theravance Biopharma Q2 Adj. EPS $0.18 Beats $0.05 Estimate, Sales $20.731M Miss $21.600M Estimate
Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.05 by 260 percent. This is a 325 percent increase over losses of $(0.08) per share from
Read original at benzingaZymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
Zymeworks Inc. announced it will report second quarter 2026 financial results on August 6, 2026, but will not host an earnings conference call due to its pending acquisition of Theravance Biopharma. The company plans to provide updates on the combined business following the expected closing of the acquisition.
Read original at globenewswire-inc